OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Friday, December 12th BRPNF, PGOG, NXHD, DLKM, EXEL, TYPE

Dec 12, 2008 (M2 PRESSWIRE via COMTEX) -- PGOG | Quote | Chart | News | PowerRating -- Our Stocks to Watch today include Bravo Resources Partners Ltd. (OTC: BRPNF), Perf Go Green Holdings Inc. (OTCBB: PGOG), Nexia Holdings Inc. (OTCBB: NXHD), Douglas Lake Minerals Inc. (OTCBB: DLKM), Exelixis Inc. (Nasdaq: EXEL | Quote | Chart | News | PowerRating) and Monotype Imaging Holdings Inc. (Nasdaq: TYPE).

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.

BRAVO RESOURCES PARTNERS LIMITED (OTC: BRPNF | Quote | Chart | News | PowerRating) "Up 25.71% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BRPNF.php

Bravo Resources Partners Ltd., is a public company trading under the symbol "BRPNF.PK." Bravo's goal is to rank among the top six gold miners in Ghana within the next five years. The company plans to do this through a combination of good quality land acquisition, joint venturing and development of quality properties. The 2009 outlook for the gold-sub industry is positive, based on the expectation of rising gold prices. Low short-term interest rates reduce the opportunity cost of holding gold as an investment, which will allow gold to continue rising if other industries decrease. The price of gold will also continue to rise because of the depleting mines and the inability to replace output. With the instability of the global markets, major world currencies will likely increase the demand for gold as a temporary reserve asset.

BRPNF News:

December 11 - Bravo Resource Partners Negotiates M.O.U. on Gold Mine With Vast Reserves in Ghana, Africa

Bravo Resource Partners Ltd. (OTC: BRPNF | Quote | Chart | News | PowerRating) announces the appointment of Mr. Jeffrey Cox President and CEO of Bravo Resource Partners, as well as the signing of a memorandum of understanding with a significant property in Ghana. Initial due diligence indicates a vast gold reserve on the property. Bravo Resources looks forward to keeping shareholders updated as to the closure of this agreement and the resulting forward action on mining activities.

PERF GO GREEN HOLDINGS INCORPORATED (OTCBB: PGOG)

Detailed Quote: http://www.otcpicks.com/quotes/PGOG.php

Company Profile: http://www.otcpicks.com/perf-go-green/perf-go-green.htm

Perf Go Green Holdings, Inc. is engaged in the creation and global marketing of 100% eco-friendly, non-toxic, food-contact-compliant, biodegradable plastic products. All Perf Go Green products are made from recycled plastics and completely break down in landfill within two years, leaving no toxic or visible residue, as compared to other plastics that take hundreds of years. Perf Go Green's corporate name reflects its "Go Green" mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment.

PGOG News:

December 12 - Perf Go Green Signs Distribution Partnership With Grocery Giant Associated Food Stores

Distribution Network Now Encompasses Stores With More Than 22,000 Retail Units

Perf Go Green Holdings, Inc. (OTCBB: PGOG | Quote | Chart | News | PowerRating) ("Perf Go Green"), a marketer and distributor of biodegradable plastics, announced a distribution partnership with Associated Food Stores ("AFS"). Beginning this month, AFS will stock and distribute Perf Go Green's 13-gallon tall kitchen trash bags and 30-gallon garage, lawn & leaf bags to its 450 retail-member locations.

"AFS - which is known by independent grocers throughout the western U.S. for its comprehensive services and innovation - is eager to help shoppers do the right thing by going green," said Perf Go Green Chairman and CEO Tony Tracy. "We're delighted to add AFS to our growing list of distributors, which now encompasses stores with a total of more than 22,000 retail units across the U.S. With each purchase of a Perf Go Green bag, households can reduce their plastic waste and contribute to a better environment while benefiting from our products' durability, unique dispensing system and other convenient features."

Rich Parkinson, CEO of AFS, added, "One of our important commitments as a company is to be environmentally responsible and find innovative ways to be more sustainable. We are excited to carry Perf Go Green bags so that we can offer our shoppers a smart alternative to traditional plastic bag products."

Associated Food Stores is an independent retailer-owned warehouse based in Salt Lake City, Utah, which provides complete warehouse facilities and services to nearly 450 grocers in eight western states.

Perf Go Green's corporate name reflects its "Go Green" mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment. Founded in November 2007, Perf Go Green premiered at the March 2008 International Home and Housewares Show in Chicago, where its products were honored for their design quality and innovation. Perf Go Green's household products - which include kitchen trash bags, garage, lawn & leaf bags, pet products and plastic drop cloths - are now available at stores with more than 22,000 retail units and online at Amazon.com and drugstore.com. Perf Go Green also distributes a comprehensive line of commercial trash bags.

NEXIA HOLDINGS INCORPORATED (OTCBB: NXHD)

Detailed Quote: http://www.otcpicks.com/quotes/NXHD.php

Company Profile: http://www.otcpicks.com/nexia-holdings/nexia-holdings.htm

Nexia Holdings, Inc., headquartered in Salt Lake City, Utah, is a diversified holdings company with operations in real estate, health & beauty, and fashion retail. Nexia owns a majority interest in Landis Lifestyle Salon (www.landissalons.com), a hair salon built around the world-class Aveda product line. Through its Style Perfect, Inc. subsidiary, Nexia owns the innovative retail and design firm Black Chandelier and its related brands. Black Chandelier currently operates one retail location and online store at www.blackchandelier.com.

NXHD News:

December 11 - Nexia Ranked in Top 40 Public Companies by Utah Business Magazine

Nexia Holdings, Inc. (OTCBB: NXHD), a diversified holdings company with operations in real estate, health & beauty, and fashion retail was recognized as the 33rd ranked public company in Utah, based upon 2007 total revenue, by the Utah Business Book of Lists 2008. This marks Nexia's first appearance on the list and the growing attention being given to Nexia's operations and results. Nexia's reported 2007 revenue of $3,232,000 reflects the growth of its operations and the success of it projects, especially in the health and beauty operations of Landis Salons, Inc., a subsidiary of Nexia.

"Nexia will seek to build upon that strong position as reported for 2007 in the Utah real estate market, which is doing much better than several harder hit areas of the country," observed company CEO Richard Surber. "We are moving forward with our real estate expansion strategy and expect those efforts and the continued growth of our salon operations in the future to move Nexia's fortunes to even better results."

DOUGLAS LAKE MINERALS (OTCBB: DLKM | Quote | Chart | News | PowerRating) "Up 43.53% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DLKM.php

DLKM is an emerging mineral exploration company focused on exploring and developing mining opportunities in Tanzania. The Company has a large portfolio of gold, copper, nickel, uranium and diamond prospecting licenses.

DLKM News:

December 11 - Douglas Lake Minerals CEO Conference Call with Webcast

Douglas Lake Minerals (OTCBB: DLKM | Quote | Chart | News | PowerRating) (Frankfurt: D60) will hold an investor conference call to provide an update on the company on December 15th at 1:00 pm pacific time, 4:00 pm eastern time.

To access the conference call, please dial one of the following numbers:

1-800-733-7571 (anywhere within Canada and the United States) 416-646-3097 (for participants dialing from the Toronto area and overseas)

To listen to this call via live or archived audio webcast please visit Douglas Lake's website at www.douglaslakeminerals.com.

A playback recording will be available at 1-877-289-8525 until the end of the business day on December 22nd, 2008. The pass code to access the playback recording is 21292260 followed by the number sign.

EXELIXIS INCORPORATED (NASDAQ: EXEL | Quote | Chart | News | PowerRating) "Up 23.59% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/EXEL.php

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase III, Phase II and Phase I clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo.

EXEL News:

December 12 - Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs

Programs include XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281, a Phase I Inhibitor of RAF Kinase

Bristol-Myers Squibb Company (NYSE: BMY) and Exelixis, Inc. (Nasdaq: EXEL | Quote | Chart | News | PowerRating) announced a global collaboration covering two novel molecules for cancer with their associated development programs: Exelixis' XL184, a small molecule inhibitor of MET, VEGFR2 and RET, which is currently in Phase III development for medullary thyroid cancer; and Exelixis' XL281, a small molecule inhibitor of RAF kinase, which is currently in Phase I development for the treatment of patients with advanced solid tumor malignancies.

Under the terms of the collaboration, Bristol-Myers Squibb agreed to pay Exelixis an upfront cash payment of $195 million for the development and commercialization rights to both programs and to make additional license payments of $45 million in 2009.

The companies have agreed to co-develop XL184. Exelixis will have the option to co-promote XL184 in the United States. The companies will share worldwide development costs and commercial profits on XL184 in the United States. Exelixis will be eligible to receive sales performance milestones of up to $150 million and double-digit royalties on sales outside the United States. The clinical development of XL184 will be directed by a joint committee. It is anticipated that Exelixis will conduct a significant portion of clinical development activities through 2010. Exelixis may opt out of the co-development of XL184, in which case Exelixis would instead be eligible to receive development and regulatory milestones of up to $295 million, double-digit royalties on XL184 product sales worldwide, and sales performance milestones.

Bristol-Myers Squibb will receive an exclusive worldwide license to develop and commercialize XL281 and will be responsible for funding all future development. Exelixis is eligible for development and regulatory milestones of up to $315 million, sales performance milestones of up to $150 million and double-digit royalties on worldwide sales of XL281.

"For nearly a decade, the foundation for our close collaborations with Exelixis has been a commitment to discover and develop new medicines to help patients prevail over serious disease," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer, and president, Research and Development of Bristol-Myers Squibb. "XL184 and XL281 represent significant new opportunities to inhibit the progression of many different tumor types. This agreement represents the next pearl in our on-going String of Pearls initiative, designed to accelerate our company's strategy to transform into a BioPharma leader by blending external scientific innovation with our own internal research and development expertise. Together with Exelixis, we intend to fully explore how these compounds can potentially extend the treatment options of patients with cancer."

"There have been many attempts to blend the best of big pharma with the best of biotech, and over the years Exelixis and Bristol-Myers Squibb have learned how to do just that. This new collaboration maximizes the capabilities and strengths of each partner and sets the stage for the aggressive development of XL184 and XL281. The collaboration provides the development programs with appropriate resources and positions both compounds to be developed to their full potential in indications with significant commercial potential," said George Scangos, president and chief executive officer of Exelixis. "Exelixis and Bristol-Myers Squibb are working toward a shared vision of maximizing the potential of these compounds to benefit patients who suffer from numerous types of cancer."

XL184 provides a novel approach to the treatment of a variety of solid tumors where signaling through MET, VEGFR2 or RET plays an important role in dysregulated tumor growth and progression. XL184 has recently begun a Phase III clinical trial in medullary thyroid cancer, a disease in which RET mutations are found in a large proportion of patients. In addition, clinical trials to exploit the MET and VEGFR2 targeting of XL184 are ongoing in patients with non-small cell lung cancer and glioblastoma. Preclinically, XL184 also exhibits inhibitory activity for MET and VEGFR2 in a variety of breast, colon and brain tumor models.

XL281 is a novel small molecule designed to selectively inhibit RAF kinase, which lies immediately downstream of RAS and is a key component of the RAS/RAF/MEK/ERK kinase signaling pathway. The RAS/RAF/MEK/ERK pathway plays a key role in the transmission of growth-promoting signals downstream of receptor tyrosine kinases. Dysregulation of this pathway plays a pivotal role in the progression of many human tumors, and inhibition of the pathway may be useful in the treatment of cancer. Phase I trials with this molecule are underway in order to select a dose and schedule for Phase II disease-directed trials.

The effectiveness of the agreement is subject to antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary regulatory approvals.

ABOUT BRISTOL-MYERS SQUIBB

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life. For more information visit www.bms.com.

MONOTYPE IMAGING HOLDINGS INCORPORATED (NASDAQ: TYPE | Quote | Chart | News | PowerRating) "Up 8.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/TYPE.php Monotype Imaging is a global provider of text imaging solutions for manufacturers and developers of consumer electronics devices including laser printers, copiers, mobile phones, digital televisions, set-top boxes, digital cameras and software applications and operating systems. The company also provides printer drivers and color imaging technologies to OEMs (original equipment manufacturers). Monotype Imaging technologies are combined with access to more than 10,000 typefaces from the Monotype , Linotype and ITC typeface libraries - home to some of the world's most widely used designs, including the Times New Roman , Helvetica and ITC Franklin Gothic typefaces. Fonts are licensed to creative and business professionals through custom font design services, direct sales or e-commerce portals. Monotype Imaging offers fonts and industry-standard solutions that support all of the world's major languages. The company is based in Woburn, Mass., with regional offices in the U.K., Germany (Linotype), Mt. Prospect, Ill., Redwood City, Calif., Boulder, Colo., Japan and China.

TYPE News:

December 11 - Monotype Imaging Adds Typefaces to Fonts.com from 15 Type Foundries

Latest Foundry Additions Help Increase Tally of Font Products Available to More than 150,000

Monotype Imaging Holdings Inc. (Nasdaq: TYPE), a leading global provider of text imaging solutions, has added typeface collections to its Fonts.com store from 15 type foundries, including Thinkdust, Brass Fonts, TypeTogether, Sherwood Type, DSType, Scriptorium, IHOF, TipografiaRamis, Canada Type, Mean Tangerine, Haiku Monkey, Cubo Fonts, Greenprint, Dutchfonts and TypeBank. The new fonts can be previewed by clicking the "foundries added" link on www.fonts.com/new.

"Adding foundries to Fonts.com is critical to ensuring our type selection remains wide-ranging, contemporary and fresh," said Allan Haley, director of words and letters at Monotype Imaging. "With fonts from IHOF and Sherwood Type that convey a historical appeal, designs from Canada Type that can only be described as cool, and fonts from TypeBank that offer a broad selection for Japanese communicators, these collections add international flavor and choice - ingredients that can never be overused."

International House of Fonts (IHOF), a division of the P22 type foundry, offers an eclectic typeface collection from designers throughout the world, with designs ranging from historical lettering to unique, contemporary offerings. The P22 Chai Tea font is a brush letter script with sweeping strokes and generous horizontal proportions. Suggesting warmth and personality, Chai Tea resembles a distinctive, hand-drawn script. IHOF fonts are available in OpenType , PostScript and TrueType formats for Apple Macintosh and Microsoft Windows systems. Prices start at $20 US.

Sherwood Type, also part of the P22 type foundry, features fonts from designer Ted Staunton. The collection is influenced by historical type designs and contains a variety of styles that include handwriting, classical Roman, Celtic, medieval, and blackletter designs. The P22 1722 typeface is based on early 18th century printing and portrays the look of uneven inking on handmade paper. Sherwood Type fonts are available in OpenType, PostScript and TrueType formats for Macintosh and Windows systems. Prices start at $20 US.

Based in Austin, Texas, Scriptorium features the work of David Nalle. The collection features decorative and calligraphic fonts based on historical and folk sources. The Abaddon typeface is an interpretation on lettering from Czech artist Alphons Mucha. Scriptorium fonts are available in PostScript and TrueType formats for Macintosh and Windows systems. Prices start at $20 US.

Formed in 2004, Canada Type is a Toronto-based foundry featuring a collection of more than 100 typefaces. The Swan Song design is a digitization of a free form calligraphy sample from British lettering artist, Rachel Yallop. Canada Type fonts are available in OpenType, PostScript and TrueType formats for Macintosh and Windows systems. Prices start at $12 US.

Formed in Tokyo more than 20 years ago, TypeBank specializes in Japanese typeface design and production. In addition to licensing its collection to graphic designers, publishers and end users, TypeBank also licenses fonts for use in consumer electronics devices such as mobile phones and laser printers. The TB Calligra Gothic family from TypeBank incorporates slightly flared strokes for an expressive interpretation of the simplistic gothic Japanese typeface style. TypeBank fonts are available in OpenType format for Macintosh and Windows systems and TrueType format for Windows systems. Prices start at $100 US.

Typefaces from Thinkdust, Brass Fonts, TypeTogether, DSType, TipografiaRamis, Mean Tangerine, Haiku Monkey, Cubo Fonts, Greenprint and Dutchfonts round out the latest foundry additions on Fonts.com, which now offers more than 150,000 font products from more than 200 foundries.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has received twenty million free trading shares from a non-controlling third party for NXHD advertising and promotional services. OTCPicks.com has been compensated eight thousand dollars by a third party (BlueWave Advisors) for PGOG advertising and promotional services. OTCPicks.com has been compensated one hundred thousand free trading shares by a non-controlling third party for BRPNF advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com e-mail: publisher@otcpicks.com Tel: +1 972 546 3740

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index